Supplementary Table 1: Studies used for determination of median PFS and OS in GBM patients treated with Temozolomide only therapy at diagnosis or with non-bevacizumab experimental agents at recurrence.
a. Newly Diagnosed GBMAuthor / Year / Treatment / Phase / # of Patients / Median Age (Range) / M:F ratio / Median F/U (95% CI) [weeks] / Median PFS (95% CI) [weeks] / Median OS (95% CI) [weeks]
Weller et al.* / 2015 / Dose Intense TMZ / II / 52 / 58 (21-62) / 34/18 / NA / 52.1 (38.2-73.9) / 42.6 (29.1-56.5)
Weller et al.* / 2015 / Dose Intense TMZ / II / 53 / 56 (37-59) / 35/18 / NA / 47.8 (40-56.1) / 46.1 (35.2-50.4)
Stupp et al. / 2005 / TMZ / III / 287 / 56 (19-70) / 185/102 / 121.7 / 30 (25.2-35.6) / 63.4 (57.4-73)
Malmstrom et al. / 2012 / TMZ / III / 93 / 70 (60-88) / 55/38 / NA / NA / 36.1 (30.9-41.3)
Gilbert et al.* / 2013 / Standard TMZ / III / 411 / NA / 239/172 / 136.9 (NA) / 23.9 (20.4-26.5) / 72.1 (64.7-78.2)
Gilbert et al.* / 2013 / Dose Dense TMZ / III / 422 / NA / 237/185 / 136.9 (NA) / 29.1 (26.9-33.5) / 64.7 (59.5-71.7)
Stupp et al. / 2015 / TMZ / III / 105 / 58 (21-80) / 67/38 / At least 78.2*** / 17.4 (14.3-22.6) / 67.8 (57.8-83)
Total: 2806
b. Recurrent GBM
Author / Year / Treatment / Phase / # of Patients / Median Age (Range) / M:F ratio / Median F/U (95% CI) [weeks] / Median PFS (95% CI) [weeks] / Median OS (95% CI) [weeks]
Rosenthal et al. / 2000 / Taxol + Estramustine phosphate / II / 20 / 45 (19-67) / 11/9 / NA / 6 (range: 3-60) / 12 (3-60)
See et al. / 2004 / 13-cis-retinoic acid / II / 85 / 51 (19-90) / 53/32 / NA / 10 (NA) / 24.6 (NA)
Ballman et al. / 2006 / Varies (See Table 1 in paper) / II / 345 / 54 (19-79) / 210/135 / NA / 7.82 (7.4-8.7) / 21.7 (20-23.5)
Groves et al. / 2006 / TMZ + Thalidomide / II / 44 / 53 (32-84) / 29/15 / NA / 15 (10-20) / NA
Puduvalli et al. / 2007 / Irinotecan + Thalidomide / II / 33 / 46.5 (21-65) / 24/8 / NA / 13 (10-24) / 36 (24-56)
Total:
527
NA = not available